Señalización PI3K / Akt / mTOR
Los inhibidores de la señalización PI3K/Akt/mTOR son compuestos que se dirigen a las vías de la fosfoinositida 3-cinasa (PI3K), la cinasa Akt y el blanco de la rapamicina en mamíferos (mTOR). Estas vías son reguladores críticos del crecimiento celular, la supervivencia, el metabolismo y la autofagia, lo que las convierte en objetivos clave en la investigación del cáncer y los trastornos metabólicos. Inhibir estas vías puede ayudar a controlar el crecimiento y la proliferación tumoral, ofreciendo potenciales estrategias terapéuticas para varios tipos de cáncer y otras enfermedades caracterizadas por una señalización celular desregulada. En CymitQuimica, ofrecemos una amplia selección de inhibidores de alta calidad de PI3K/Akt/mTOR para apoyar su investigación en oncología, señalización celular y enfermedades metabólicas.
Subcategorías de "Señalización PI3K / Akt / mTOR"
- AMPK(158 productos)
- ATM / ATR(71 productos)
- ADN-PK(51 productos)
- EGFR(572 productos)
- MELK(7 productos)
- PDK(9 productos)
- PI3K(242 productos)
- Quinasa S6(9 productos)
- gsk-3(112 productos)
- mTOR(144 productos)
Mostrar 2 subcategorías más
Se han encontrado 1038 productos de "Señalización PI3K / Akt / mTOR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
DS06652923
<p>DS06652923 is an orally active inhibitor targeting EGFR triple mutations. It exhibits growth-inhibitory effects on Ba/F3EGFRdel19/T90M/C795S cells, with a GI50 value of 9.4 nM. Additionally, DS06652923 induces tumor regression in the Ba/F3 syngeneic transplantation model.</p>Forma y color:Odour SolidDA-143
<p>DA-143 is a selective inhibitor of DNA-PKcs (IC50: 2.5 nM), demonstrating disparate inhibitory effects on mTOR, PI3KΔ, and ATM, with IC50 values of 280 nM, 106 nM, and 6,594 nM, respectively. This compound effectively blocks the phosphorylation of DNA-PKcs substrates and enhances the sensitivity of cancer cells to doxorubicin.</p>Forma y color:Odour SolidPI3Kδ-IN-8
CAS:<p>PI3Kδ-IN-8 is a powerful and specific oral inhibitor of PI3Kδ, exhibiting an IC50 of 3.3 nM.</p>Fórmula:C28H21F2N7OForma y color:SolidPeso molecular:509.521mTOR inhibitor WYE-28
CAS:<p>Compound 28 (mTOR inhibitor WYE-28) is a selective inhibitor of mTOR (IC50=0.08 nM). Also inhibits PI3Kα (IC50 6 nM).</p>Fórmula:C30H34N8O5Forma y color:SolidPeso molecular:586.653PI3Kα-IN-25
<p>PI3Kα-IN-25 (Compound Djh1) is a selective inhibitor of PI3Kα, suitable for research in triple-negative breast cancer.</p>Fórmula:C21H19ClN4O4Forma y color:SolidPeso molecular:426.853HER2-IN-14
CAS:<p>HER2-IN-14 (Compound 34) is a potent inhibitor of HER2, achieving an inhibitory concentration (IC50) of 18 nM.</p>Fórmula:C26H23ClF2N8O3Forma y color:SolidPeso molecular:568.96EGFR-IN-124
<p>EGFR-IN-124 (compound 10A) is an EGFR inhibitor with an IC50 value of 0.54 μM, utilized in cancer research.</p>Forma y color:Odour SolidEGFR-IN-127
<p>EGFR-IN-127 is an ATP-competitive inhibitor targeting EGFR, with IC50 values of 136.3 nM for EGFRdel19 and 161.2 nM for EGFRdel19/T790M/C797S. This compound holds potential for the study of non-small cell lung cancer (NSCLC).</p>Forma y color:Odour SolidHL-8
CAS:<p>HL-8, a PROTAC targeting PI3K, degrades it fully at 10 μM in 8h, useful in cancer research.</p>Fórmula:C57H59F2N11O9S2Forma y color:SolidPeso molecular:1144.27GSK-3β inhibitor 21
<p>GSK-3β Inhibitor21 (compound 44) is an ATP-competitive inhibitor of GSK-3β with an IC50 value of 6.06 µM, characterized by its ability to inhibit tau phosphorylation and prevent amyloid protein aggregation. This compound is utilized in the research of Alzheimer's disease.</p>Forma y color:Odour SolidCetuximab MMAE
<p>Cetuximab-MMAE, an antibody-drug conjugate (ADC), combines an EGFR-targeting antibody with Monomethyl auristatin E (MMAE) to investigate colorectal and head and neck cancers.</p>Forma y color:LiquidPeso molecular:150 kDaVarlitinib Tosylate
CAS:<p>Varlitinib Tosylate is a selective and potent inhibitor of ErbB1(EGFR) and ErbB2(HER2).</p>Fórmula:C36H35ClN6O8S3Pureza:98%Forma y color:SolidPeso molecular:811.34PI3K-IN-22
CAS:<p>PI3K-IN-22 is a dual kinase inhibitor of PI3Kα and mTOR, with IC50s of 0.9 and 0.6 nM respectively. PI3K-IN-22 could be used in cancer.</p>Fórmula:C31H35F3N8O3Forma y color:SolidPeso molecular:624.66HER2/neu (654-662) GP2
CAS:<p>Phage display selected Affibody ligands for HER2/neu from a protein library based on a 58-residue Staphylococcal protein A Z domain.</p>Fórmula:C42H77N9O11Pureza:98%Forma y color:SolidPeso molecular:884.11EGFR/PI3Kα-IN-1
<p>EGFR/PI3Kα-IN-1 (compound 30k), a dual EGFR/PI3Kα inhibitor, exhibits potent activity with IC 50 values of 3.6 nM (EGFRL858R/T790M) and 30 nM (PI3Kα). It effectively inhibits tumor cell proliferation and demonstrates significant anticancer activity.</p>Fórmula:C50H49N11O5SForma y color:SolidPeso molecular:916.06RMC-4529
CAS:<p>RMC-4529 is a chemical compound that demonstrates potent inhibition, with an IC50 value of 1.0 nM, against p-4E-BP1-(T37/46) in mTOR kinase cellular assays.</p>Fórmula:C90H139N13O23Forma y color:SolidPeso molecular:1771.17Tephrosin
CAS:<p>Tephrosin induces degradation of of EGFR and ErbB2 by inducing internalization of the receptors, has potent antitumor activities.</p>Fórmula:C23H22O7Pureza:98%Forma y color:SolidPeso molecular:410.42Amdizalisib
CAS:<p>Amdizalisib is a PI3K inhibitor and used for the research of inflammatory disease, autoimmune disease or cancer.</p>Fórmula:C19H15ClN8Forma y color:SolidPeso molecular:390.84IBI-334
<p>IBI-334 is a bispecific antibody targeting both B7-H3 and EGFR. It features an EGFR arm responsible for signal blocking, connected to a modified B7-H3 arm that ensures optimal affinity and binding. The antibody is afucosylated to enhance its antibody-dependent cellular cytotoxicity (ADCC) effects. IBI-334 is widely applicable in EGFR-driven solid tumors.</p>Forma y color:Odour LiquidUmbralisib R-enantiomer
CAS:<p>Umbralisib R-enantiomer (RP5264 R-enantiomer) is a delta inhibitor of PI3K and a less active enantiomer of TGR-1202.</p>Fórmula:C31H24F3N5O3Pureza:97.34%Forma y color:SolidPeso molecular:571.55
